Projects and registries

Ongoing projects and registries

 
TITLE

Long-term outcomes of patients with coronary spasm associated with eosinophilia: the SPASMEO multicentric retrospective study

scientific director

Dr Matthieu Groh, Internal Medicine Department, CEREO (Reference coordinating center of hypereosinophilic syndrome in France) – Foch Hospital

AIM

– To set up the first international multicentric cohort of patients with eosinophilia-associated coronary vasospasms to provide an in-depth report of the clinical picture and MRI findings of EGPA
– To estimate survival rates, shed light on predictors of relapse
– Eventually, to provide a practical data-driven therapeutic algorithm for EGPA.

 
TITLE

Eosinophilia-related temporal arteritis

PROMOTER/PI

Prof Benjamin Terrier, Cochin Hospital, Paris, France

AIM

This study will allow to specify the existence or not of an eosinophilic temporal arteritis, whose characteristics and prognosis could differ from giant cell arteritis. Also, the therapeutic management could be specified.

TITLE

Impact of mepolizumab on patient-reported outcomes in eosinophilic granulomatosis with polyangiitis by using ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire: the faster the better?

PROMOTER/PI

Sara Monti and Paolo Delvino, University of Pavia, Italy

AIM

To assess the effect of mepolizumab on patient-reported outcomes in patients with refractory ENT manifestations and/or asthma secondary to EGPA by using the AAV PRO questionnaire.

TITLE

Effectiveness and Safety of Benralizumab  in patients with EGPA: a retrospective study

PROMOTER/PI

Giacomo Emmi and Augusto Vaglio, University of Firenze, Italy

AIM

To investigate retrospectively the efficacy and safety of benralizumab in EGPA patients.

TITLE

EGPA onset during biologic treatment for severe asthma

PROMOTER/PI

Marco Caminati, University of Verona,  Italy

AIM

To assess the prevalence of EGPA onset during the course of biologic treatment with anti-IL-5, anti-IgE or anti IL-4/IL-13 treatments, prescribed for severe asthma.

TITLE

Efficacy and safety of Rituximab in EPGA patients with renal involvement

PROMOTER/PI

Dario Roccatello, University of Torino, Italy

AIM
To assess the efficacy and safety of Rituximab in EPGA with renal involvement 
Study design: retrospective observational multi-centre
Inclusion criteria: patients with 1) EPGA and 2) biopsy proven-GN treated with RTX
TITLE

Therapeutic approaches in myeloperoxidase (MPO)-associated interstitial lung disease (ILD): a multicentre study

PROMOTER/PI

Giacomo Emmi, University of Firenze, Italy

AIM
– To investigate the pattern of use of different treatments (immunosuppressants, anti-
fibrotics or their combination) in patients with MPO-associated ILD
– To investigate the effectiveness of immunosuppressants (+/- anti-fibrotic agents) vs
anti-fibrotic agents in patients with MPO-associated ILD.
– To assess the rate of acute exacerbations following remission during treatment with
immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic agents;
– To assess the occurrence of AAV during treatment with immunosuppressants (+/-
anti-fibrotic agents) vs anti-fibrotic agents;
– To assess potential differences in term of prognosis (hospitalization, death) in
patients receiving immunosuppressants (+/- anti-fibrotic agents) vs anti-fibrotic
agents;
– To assess the safety of the treatment with immunosuppressants (+/- anti-fibrotic
agents) vs anti-fibrotic agents

INTERVIEW BY THE EXPERTS